Other
NMOSD
5
Pipeline Programs↗
4
Active Trials↗
5
Companies Involved↗
NMOSD is an early-stage landscape with 5 programs across 5 companies. The most active players are Roche, AstraZeneca, Horizon Therapeutics Ireland DAC. 5 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Analysis
Trial Status
7
clinical trials
Completed3 · 43%
Recruiting2 · 29%
Not yet recruiting2 · 29%
Clinical Trials
Trial Activity
7 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)